...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes
【24h】

Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes

机译:共刺激分子TNFSF4与造血干细胞移植结果的遗传多态性分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Despite stringent procedures to secure the best HLA matching between donors and recipients, life-threatening complications continue to occur after hematopoietic stem cell transplantation (HSCT). Studying single nucleotide polymorphism (SNP) in genes encoding costimulatory molecules could help identify patients at risk for post-HSCT complications. In a stepwise approach we selected SNPs in key costimulatory molecules including CD274, CD40, CD154, CD28, and TNFSF4 and systematically analyzed their association with post-HSCT outcomes. Our discovery cohort analysis of 1157 HLA-A, -B, -C, -DRB1, and -DQB1 matched cases found that patients with donors homozygous for the C variant of rs10912564 in TNFSF4 (48%) had better disease-free survival (P =.029) and overall survival (P =.009) with less treatment-related mortality (P =.006). Our data demonstrate the TNFSF4C variant had a higher affinity for the nuclear transcription factor Myb and increased percentage of TNFSF4-positive B cells after stimulation compared with CT or TT genotypes. However, these associations were not validated in a more recent cohort, potentially because of changes in standard of practice or absence of a true association. Given the discovery cohort, functional data, and importance of TNFSF4 in infection clearance, TNFSF4C may associate with outcomes and warrants future studies. (C) 2016 American Society for Blood and Marrow Transplantation.
机译:尽管有严格的程序来确保供体和受体之间的最佳HLA匹配,但造血干细胞移植(HSCT)后仍继续发生危及生命的并发症。研究编码共刺激分子的基因中的单核苷酸多态性(SNP)可以帮助识别处于HSCT后并发症风险中的患者。我们采用逐步方法,在包括CD274,CD40,CD154,CD28和TNFSF4在内的关键共刺激分子中选择了SNP,并系统地分析了它们与HSCT后结果的相关性。我们对1157个HLA-A,-B,-C,-DRB1和-DQB1匹配病例的发现队列分析发现,对于TNFSF4中rs10912564 C变体纯合的供体患者(48%),其无病生存期更好(P = .029)和总体存活率(P = .009),与治疗相关的死亡率较低(P = .006)。我们的数据表明,与CT或TT基因型相比,刺激后TNFSF4C变体对核转录因子Myb的亲和力更高,并且TNFSF4阳性B细胞的百分比增加。但是,这些关联在最近的队列中未得到验证,这可能是由于实践标准的改变或缺乏真正的关联。考虑到TNFSF4的发现队列,功能数据和重要性,TNFSF4C可能与预后相关,值得进一步研究。 (C)2016美国血液和骨髓移植学会。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号